Tag Archives: KERX

Healthcare Sector Highlights: Health Management (NYSE:HMA), AngioDynamics (NASDAQ:ANGO) – HMA, ANGO, THC, STAA, KERX, AFFX

Posted on April 10, 2013 by Thomas Vedder

Healthcare sector finished higher on Tuesday trading session and sector hiked +0.22%. If we consider key movers of this sector so STAAR Surgical Company (NASDAQ:STAA) and Keryx Biopharmaceuticals (NASDAQ:KERX) were major percentage gainers while key percentage decliner was Affymetrix, Inc …

Posted in Healthcare, Latest Headlines | Tagged AFFX, Affymetrix, AngioDynamics, ANGO, Health Management Associates, HMA, KERX, Keryx Biopharmaceuticals, NASDAQ:AFFX, NASDAQ:ANGO, NASDAQ:KERX, NASDAQ:STAA, NYSE:HMA, NYSE:THC, STAA, STAAR Surgical, Tenet Healthcare, THC | Comments Off

Healthcare Sector Recap: HCA Holdings (HCA) and Becton, Dickinson (BDX) Post Quarterly Results – HCA, BDX, PFE, NBIX, KERX, RMTI

Posted on February 6, 2013 by Thomas Vedder

Healthcare sector finished higher on Tuesday with +0.81% change. If we look at the best movers of the sector so Neurocrine Biosciences, Inc (NASDAQ:NBIX) and Keryx Biopharmaceuticals (NASDAQ:KERX) were major percentage gainer while key percentage decliner was Rockwell Medical Inc …

Posted in Healthcare, Latest Headlines | Tagged BDX, Becton, Dickinson, HCA, HCA Holdings, KERX, Keryx Biopharmaceuticals, NASDAQ:KERX, NASDAQ:NBIX, NASDAQ:RMTI, NBIX, Neurocrine Biosciences, NYSE:BDX, NYSE:HCA, NYSE:PFE, PFE, Pfizer, RMTI, Rockwell Medical | Comments Off

HUMHumana (NYSE:HUM) Declares fiscal Q4 Results; Earnings Hikes 3.5% – HUM, KERX, GILD, BSX, PPHM, MRK, HLF, AET, CI

Posted on February 4, 2013 by Geoff Noir

Humana Inc (NYSE:HUM) announced on Monday that fiscal Q4 earnings moved down 3.5 percent as higher coverage outlays masked firm’s revenue expansion from higher membership.

The health-care company done it’s almost $850 million purchase of Metropolitan Health Networks Inc in …

Posted in Healthcare, Latest Headlines | Tagged AET, Aetna, Boston Scientific, BSX, CI, Cigna, GILD, Gilead Sciences, Herbalife, HLF, HUM, Humana, KERX, Keryx Biopharmaceuticals, Merck, MRK, NASDAQ:GILD, NASDAQ:KERX, NASDAQ:PPHM, NYSE:AET, NYSE:BSX, NYSE:CI, NYSE:HLF, NYSE:HUM, NYSE:MRK, Peregrine Pharmaceuticals, PPHM | Comments Off

Healthcare Stocks Finishes Higher; Merck (MRK) Fiscal Fourth Quarter Profit Tumbles while Perrigo (PRGO) Acquires Velcera in $160 Million Deal – MRK, PRGO, PFE, ABAX, PPHM, KERX

Posted on February 2, 2013 by Thomas Vedder

Healthcare sector responded positively on Friday’s trading session and sector moved up +0.81%. If we look at the key movers of the sector so Abaxis Inc (NASDAQ:ABAX) and Peregrine Pharmaceuticals (NASDAQ:PPHM) were major percentage gainers while key decliner was Keryx …

Posted in Healthcare, Latest Headlines | Tagged ABAX, Abaxis, KERX, Keryx, Merck, MRK, NASDAQ:ABAX, NASDAQ:KERX, NASDAQ:PPHM, NASDAQ:PRGO, NYSE:MRK, NYSE:PFE, Peregrine Pharmaceuticals, Perrigo, PFE, Pfizer, PPHM, PRGO | Comments Off

Aetna (NYSE:AET) Net Plunges 49% in Fiscal Q4 on Reimbursement Settlement – AET, BSX, ABIO, KERX, CLSN, GNBT, ABBV, CI, UNH

Posted on January 31, 2013 by Geoff Noir

Aetna Inc (NYSE:AET) reported that fiscal Q4 profit moved down 49% after the third-biggest United States health insurer decided to pay around $120 million to fix a court case regarding its payments to doctors.

The Hartford, Connecticut-based Aetna reported in …

Posted in Healthcare, Latest Headlines | Tagged ABBV, AbbVie, ABIO, AET, Aetna, ARCA biopharma, Boston Scientific, BSX, Celsion, CI, Cigna, CLSN, Generex Biotechnology, GNBT, KERX, Keryx Biopharmaceuticals, NASDAQ:ABIO, NASDAQ:CLSN, NASDAQ:KERX, NYSE:ABBV, NYSE:AET, NYSE:BSX, NYSE:CI, NYSE:UNH, OTC:GNBT, UNH, UnitedHealth | Comments Off

Healthcare Sector Recap; Boston Scientific (BSX) Plans to Lower 1000 Jobs while Eli Lilly (LLY) Profit Tumble – BSX, LLY, PFE, KERX, RPRX, SNTA

Posted on January 30, 2013 by Geoff Noir

Last trading session data confirmed that healthcare sector reacted positively with +0.99% change. Keryx Biopharmaceuticals (NASDAQ:KERX) and Repros Therapeutics Inc (NASDAQ:RPRX) were major percentage gainers in this sector while key decliner was Synta Pharmaceuticals Corp (NASDAQ:SNTA).

The Natick, Massachusetts- based …

Posted in Healthcare, Latest Headlines | Tagged Boston Scientific, BSX, Eli Lilly, KERX, Keryx Biopharmaceuticals, LLY, NASDAQ:KERX, NASDAQ:RPRX, NASDAQ:SNTA, NYSE:BSX, NYSE:LLY, NYSE:PFE, PFE, Pfizer, Repros Therapeutics, RPRX, SNTA, Synta | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.